MedTrace Logo

Ameliorating Contrast Induced Nephropathy After Coronary Angiography

NCT06139952 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-07-11

No results posted yet for this study

Summary

Given the limited understanding of the impact of statin and N-acetyl cysteine use before angiography in preventing contrast-induced nephropathy (CIN), the objective of this study is to evaluate the effectiveness of atorvastatin in preventing CIN among patients undergoing coronary angiography.

Conditions

Interventions

DRUG

Atorvastatin 80mg

Atorvastatin 80mg taken Once before coronary angiography

DRUG

N-acetyl cysteine

200mg 3 times daily 2 days before coronary angiography

OTHER

Normal Saline

adequate hydration using Normal Saline (1ml/kg/hr)

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-03-01
Completion
2024-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06139952 on ClinicalTrials.gov